Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Syphilis remains a significant health problem worldwide, with an estimated 10.6 million new
cases per year. Due to shared transmission route and risk factors, co-infection with syphilis
and Human Immunodeficiency Virus (HIV) is not uncommon. Several studies have evaluated the
response to syphilis treatment in HIV-infected patients. They support the claim that patients
with HIV have a slower decrease in syphilis antibody titers, and that they may progress to
neurosyphilis in earlier stages.
The Center for Disease Control and Prevention's Sexually Transmitted Disease Treatment
Guidelines has advocated treating HIV-infected patients who have primary, secondary syphilis
or early latent syphilis with the same doses of penicillin as for HIV-uninfected patients
(single dose of 2.4 million units of benzathine penicillin G). The investigators designed a
randomized controlled trial in order to compare the efficacy of three- versus single-dosed
regimens of intramuscular benzathine penicillin G (BPG) for the treatment of early syphilis
in HIV-infected patients.
Phase:
Phase 4
Details
Lead Sponsor:
Baylor College of Medicine
Treatments:
Penicillin G Penicillin G Benzathine Penicillin G Procaine Penicillins